Abuse of prescription opioids continues to be a serious public health concern, with as many as 12.5 million individuals aged 12 or older reporting nonmedical use of prescription pain relievers in 2015. Oxycodone ARIR is the first abuse-deterrent formulation of an IR opioid approved by the Food and Drug Administration and was developed to have similar relative bioavailability to IR oxycodone. Patients can be converted from IR oxycodone to the same dose and dosing regimen of Oxycodone ARIR. It has been demonstrated that when crushed and taken intranasally, Oxycodone ARIR has a 47% and a 23% reduction in mean maximum drug liking compared with crushed intranasal IR oxycodone and intact oral Oxycodone ARIR, respectively.
Explore related content and topics
Blog
Ask the Experts: What Do We Need to Know About ALZ and other Brain-Related Illnesses?
Many people have heard of brain-related illnesses such as Alzheimer’s (ALZ). In honor of Brain Awareness Month, we shed some light on ALZ and other…
Blog
What Epilepsy Awareness Means for Research and Treatment
Epilepsy affects about 65 million around the world, and many don’t get the treatment they need. This article speaks to the importance of…
Newsletter
Industry Watch
With fall in the air in the northern hemisphere, it’s also a week full of noteworthy news in clinical development. New research shines a light on…